135 related articles for article (PubMed ID: 30185536)
21. Measurement of genome-wide DNA methylation predicts survival benefits from chemotherapy in non-small cell lung cancer.
Mo ML; Ma J; Chen Z; Wei B; Li H; Zhou Y; Shi H; Tolani B; Jin JQ; Tseng HH; Shen D; Zhan Y; Li J; Jablons DM; Zhang RQ; Guo Y; He B; Zhou HM
J Cancer Res Clin Oncol; 2015 May; 141(5):901-8. PubMed ID: 25367137
[TBL] [Abstract][Full Text] [Related]
22. TMEM196 hypermethylation as a novel diagnostic and prognostic biomarker for lung cancer.
Liu WB; Han F; Huang YS; Chen HQ; Chen JP; Wang DD; Jiang X; Yin L; Cao J; Liu JY
Mol Carcinog; 2019 Apr; 58(4):474-487. PubMed ID: 30536447
[TBL] [Abstract][Full Text] [Related]
23. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer.
Harada H; Miyamoto K; Yamashita Y; Taniyama K; Mihara K; Nishimura M; Okada M
Cancer Med; 2015 Oct; 4(10):1536-46. PubMed ID: 26276761
[TBL] [Abstract][Full Text] [Related]
24. Glutathione S-transferase PI (GST-PI) mRNA expression and DNA methylation is involved in the pathogenesis and prognosis of NSCLC.
Grimminger PP; Maus MK; Schneider PM; Metzger R; Hölscher AH; Sugita H; Danenberg PV; Alakus H; Brabender J
Lung Cancer; 2012 Oct; 78(1):87-91. PubMed ID: 22884253
[TBL] [Abstract][Full Text] [Related]
25. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.
Brabender J; Usadel H; Danenberg KD; Metzger R; Schneider PM; Lord RV; Wickramasinghe K; Lum CE; Park J; Salonga D; Singer J; Sidransky D; Hölscher AH; Meltzer SJ; Danenberg PV
Oncogene; 2001 Jun; 20(27):3528-32. PubMed ID: 11429699
[TBL] [Abstract][Full Text] [Related]
26. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
27. Long interspersed nuclear element 1 hypomethylation is a marker of poor prognosis in stage IA non-small cell lung cancer.
Saito K; Kawakami K; Matsumoto I; Oda M; Watanabe G; Minamoto T
Clin Cancer Res; 2010 Apr; 16(8):2418-26. PubMed ID: 20371677
[TBL] [Abstract][Full Text] [Related]
28. Promoter methylation of BRMS1 correlates with smoking history and poor survival in non-small cell lung cancer patients.
Yang J; Shen Y; Liu B; Tong Y
Lung Cancer; 2011 Nov; 74(2):305-9. PubMed ID: 21726917
[TBL] [Abstract][Full Text] [Related]
29. LRRC3B is downregulated in non-small-cell lung cancer and inhibits cancer cell proliferation and invasion.
Kan L; Li H; Zhang Y; Wang J; Niu H; Jiang H; Zhang M; Bai X; He P
Tumour Biol; 2016 Jan; 37(1):1113-20. PubMed ID: 26276358
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation markers and early recurrence in stage I lung cancer.
Brock MV; Hooker CM; Ota-Machida E; Han Y; Guo M; Ames S; Glöckner S; Piantadosi S; Gabrielson E; Pridham G; Pelosky K; Belinsky SA; Yang SC; Baylin SB; Herman JG
N Engl J Med; 2008 Mar; 358(11):1118-28. PubMed ID: 18337602
[TBL] [Abstract][Full Text] [Related]
31. LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
Imperatori A; Sahnane N; Rotolo N; Franzi F; Nardecchia E; Libera L; Romualdi C; Cattoni M; Sessa F; Dominioni L; Furlan D
Lung Cancer; 2017 Jun; 108():83-89. PubMed ID: 28625654
[TBL] [Abstract][Full Text] [Related]
32. Molecular Alterations and Expression Dynamics of LATS1 and LATS2 Genes in Non-Small-Cell Lung Carcinoma.
Malik SA; Khan MS; Dar M; Hussain MU; Shah MA; Shafi SM; Mudassar S
Pathol Oncol Res; 2018 Apr; 24(2):207-214. PubMed ID: 28434174
[TBL] [Abstract][Full Text] [Related]
33. Down-regulation of miR-503 expression predicate advanced mythological features and poor prognosis in patients with NSCLC.
Liu L; Qu W; Zhong Z
Int J Clin Exp Pathol; 2015; 8(5):5609-13. PubMed ID: 26191272
[TBL] [Abstract][Full Text] [Related]
34. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
[TBL] [Abstract][Full Text] [Related]
35. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic silencing of LRRC3B in colorectal cancer.
Tian XQ; Zhang Y; Sun D; Zhao S; Xiong H; Fang J
Scand J Gastroenterol; 2009; 44(1):79-84. PubMed ID: 18815942
[TBL] [Abstract][Full Text] [Related]
37. Epithelial-specific methylation marker: a potential plasma biomarker in advanced non-small cell lung cancer.
Vinayanuwattikun C; Sriuranpong V; Tanasanvimon S; Chantranuwat P; Mutirangura A
J Thorac Oncol; 2011 Nov; 6(11):1818-25. PubMed ID: 21964525
[TBL] [Abstract][Full Text] [Related]
38. [LRRC3B is Downregulated in Non-small Cell Lung Cancer and Connected with Cell Proliferation and Invasion].
Kan L; Zhang M; He P
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):177-83. PubMed ID: 27118644
[TBL] [Abstract][Full Text] [Related]
39. Association of RASSF1A and p63 with poor recurrence-free survival in node-negative stage I-II non-small cell lung cancer.
Ko E; Lee BB; Kim Y; Lee EJ; Cho EY; Han J; Shim YM; Park J; Kim DH
Clin Cancer Res; 2013 Mar; 19(5):1204-12. PubMed ID: 23319821
[TBL] [Abstract][Full Text] [Related]
40. CDKN2A (p16) promoter hypermethylation influences the outcome in young lung cancer patients.
Bradly DP; Gattuso P; Pool M; Basu S; Liptay M; Bonomi P; Buckingham L
Diagn Mol Pathol; 2012 Dec; 21(4):207-13. PubMed ID: 23111194
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
